Health
New Covid-19 vaccine demonstrates ’89 efficacy’ with UK having 60m orders – Bridport and Lyme Regis News
A trial was carried out in conjunction with the UK Government’s Vaccine Taskforce.
An experimental Covid-19 vaccine appears to offer strong protection in late-stage UK and South Africa studies, said manufacturer Novavax.The UK has secured access to 60 million doses of the vaccine, called NVX-CoV2373.The protein-based vaccine candidate was shown to be 89.3% effective at preventing coronavirus in participants in its Phase 3 clinical trial in the UK, which enrolled more than 15,000 people between 18-84, of which 27% were older than 65, Novavax said.
“NVX-CoV2373 is the first vaccine…
-
Noosa News24 hours agoBasic cyber steps can block most attacks – Proctor
-
Noosa News19 hours agoWhat instrument did Japan’s heavy-metal PM play? Take the Brisbane Times Quiz
-
Business11 hours agoCould a small investor today match the historic returns of Warren Buffett?
-
Noosa News22 hours agoCompetition watchdog approves Elders’ $475m acquisition of agribusiness rival Delta